Treatments - Currently, there are no FDA approved treatments for COVID-19. ydroxychloroquine sulfate It was reported in the journal Clinical Infectious Diseases on March 9,malaria drug hydroxychloroquine effective, killing, coronavirus in laboratory.

COVID-19: Prevention & Investigational Treatments

Other names: 2019 Novel Coronavirus; 2019-nCoV; Coronavirus; Novel Coronavirus Pneumonia; SARS-CoV-2 Infection

Updated - March 19, 2020 J.Stewart BPharm

https://www.drugs.com/condition/covid-19.html 

Mín upplifun.

FDA er (þessu má fletta upp á) leifisstofnun fyrir öryggi fólksins í Bandaríkjunum og er einkastofnun. Munum að sagt var í orkumálunum í Kaliforníu, það er öskrað á okkur, og við reynum að nota gróðaflækjku til að hluthafar verði ánægðir.

Það er að mig minnir, 2 til 4 milljarðar dollarar sem er greitt fyrir að fá meðal samþykkt frá stofnuninni. Það er Blog hjá mér sem nefnir þetta. 

000

slóð

Stofnfrumuaðgerðir virðast virka, stofnfrumurnar virðast fara út í líkamann og endurbyggja hann. Þær virðast geta breyst í aðrar frumur líkamans og endurnýjað hann. Fólkið streymir í þessar aðgerðir, og er tilbúið að greiða þúsundir dollara fyrir.

12.8.2019 | 20:14

000

Sýnishorn

Treatments

Currently, there are no FDA approved treatments for COVID-19.

• Several pharmaceutical companies and research organizations worldwide are involved in the development of potential vaccines.
• mRNA-1273 A novel coronavirus vaccine called mRNA-1273 (Moderna, Inc.) has been shipped to the National Institute of Allergy and Infectious Diseases ready for use in a Phase 1 study.
• Tonix Pharmaceuticals Holding Corp. has announced it is researching the development of a potential vaccine against COVID-19 using its proprietary horsepox virus platform.
• Researchers in Israel are working to adapt a vaccine that is effective against avian coronavirus Infectious Bronchitis Virus (IBV) to work as a vaccine against COVID-19 in humans.
• Remdesivir An investigational antiviral drug called remdesivir is being studied in clinical trials in China and Nebraska, USA.
• Lopinavir and ritonavir A drug combination called lopinavir/ritonavir approved to treat HIV under the brand name Kaletra is being studied in combination with the flu drug oseltamivir (Tamiflu) in Thailand. It was reported on February 18, 2020 that an elderly Chinese woman, the first patient to receive the "Thai cocktail" in Bangkok's Rajvithi Hospital, had made a complete recovery after suffering from severe COVID-19-related pneumonia.
  Update: March 18, 2020 -- According to a study in the New England Journal of Medicine, the lopinavir/ritonavir combination showed no benefit over standard care in hospitalized adult patients with severe COVID-19.
• Favipiravir An antiviral drug called favipiravir which was reported February 17, 2020 to have received marketing approval in China for the treatment of influenza, was also approved for use in clinical trials as a treatment for novel coronavirus pneumonia.
• Fingolimod An approved drug called fingolimod (marketed under the brand name Gilenya for the treatment of relapsing forms of multiple sclerosis) is being studied as a treatment for COVID-19 at the First Affiliated Hospital of Fujian Medical University in Fuzhou, China.
• Methylprednisolone A widely used glucocorticoid called methylprednisolone is being studied for safety and effectiveness in the treatment of novel coronavirus pneumonia in a number of hospitals in the Hubei province of China.
• Chloroquine phosphate The older anti-malaria drug chloroquine has been shown to have a wide range of antiviral effects, including anti-coronavirus. Studies in Guangdong Province in China suggest that chloroquine may help improve patient outcomes in people with novel coronavirus pneumonia.
• Hydroxychloroquine sulfate It was reported in the journal Clinical Infectious Diseases on March 9 that the malaria drug hydroxychloroquine was effective in killing the coronavirus in laboratory experiments. Hydroxychloroquine was first approved by the FDA in 1995 under the brand name Plaquenil, and it is also used in the treatment patients with lupus and arthritis.
• Bevacizumab A VEGF inhibitor called bevacizumab (marketed under the brand name Avastin for certain types of cancer) being studied as a treatment for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in critically ill patients with COVID-19 pneumonia at the Qilu Hospital of Shandong University in Jinan, China.

 000

Egilsstaðir, 21.03.2020  Jónas Gunnlaugsson